Pharma product developer to shed 20 jobs after €2m losses in first half
The pharma product developer is reviewing its business strategies, having also suffered losses of €800,000 in the prior six-month period. Revenue for the first half of 2011 dropped by more than €1.5m to €1.2m, principally due to the completion of some development work for its Danish-based partner, pharmaceutical company Novo Nordisk.
Merrion’s half-year accounts report stated: “Based on financial projections for the group, the company’s directors are satisfied that the group can support itself for a period of at least 12 months from the date of approval of the interim financial statements. Consequently, the directors have adopted the going concern basis in the preparation of the interim financial statements.